

Barcelona,
September, 16th 2018

ALMIRALL ANNOUNCES CFO LEADERSHIP TRANSITION: MIKE McCLELLAN TO JOIN ALMIRALL ON NOVEMBER 11 AS NEW GROUP CFO

Almirall announced today that Mike McClellan will join as new CFO on November 11, 2019.

He will succeed David Nieto, who has decided to step down from his role as CFO. David will ensure a smooth transition with Mike over the next period.

Mike is currently Group CFO and Executive Vice President at Teva based in Tel Aviv, Israel.

Before being nominated Group CFO at Teva in 2017, he was Senior Vice President and CFO of the Global Specialty Medicines business.

Before joining Teva, Mike had a long and distinguished career in the Sanofi Group, where he was CFO for Sanofi North America from 2012 to 2015. He served as CFO for Sanofi Europe from 2010 to 2012 and had held several country CFO roles in major countries such as the UK.

Peter Guenter, Chief Executive Officer, Almirall, declared: "I am very excited that we were able to attract Mike McClellan to Almirall. He has an impressive track record in the pharmaceutical industry, most recently as Group CFO of Teva. Moreover, during my Sanofi days, I worked directly together with Mike both in his CFO Europe and CFO US role, precisely the 2 territories which are strategic to Almirall.

Being able to attract somebody of the caliber of Mike also demonstrates that Almirall is increasingly able to attract top performers, based upon our attractive growth story and our ambition to develop best in class new medicines to patients with severe unmet medical needs.

Last, on behalf of the Board of Directors of Almirall and the broader leadership team, I would like to thank David for his dedication and contributions as CFO over the last years. He joined us at a difficult moment for the company and has been pivotal in its financial turnaround. He has been instrumental in reducing our cost base, attracting key talent and prepare Almirall for its new growth phase. We wish him every success for his future".

David Nieto stated: "I have valued the opportunity to serve as Almirall CFO and to lead the finance organization. Almirall has the strength and capabilities to ensure its continued growth and success in medical dermatology, and I wish everyone here well."

Mike McClellan shared: "I look forward to joining Almirall during this exciting phase for the company. I am impressed by the achievements of the last 2 years and I am eager to contribute to bring Almirall to the next level. I plan to relocate to Europe in November to join this impressive team."

About Almirall

Almirall is a leading skin-health focused global pharmaceutical company that partners with healthcare professionals, applying Science to provide medical solutions to patients and future generations. Our efforts are focused on fighting against skin health diseases and helping people feel and look their best. We support healthcare professionals by continuous improvement, bringing our innovative solutions where they are needed.

The company, founded almost 75 years ago with headquarters in Barcelona, is listed on the Spanish Stock Exchange (ticker: ALM). Almirall has been key in value creation to society according to its commitment with to major shareholders and through its decision to help others, to understand their challenges and to use Science to provide solutions for real life. Total revenues in 2018 were 811 million euros. More than 1,800 employees are devoted to Science.

Media contact:

BCW

Adriana Ibarguen

adriana.ibarguen@bcw-global.com

Tel.: + (34) 91 384 67 20

Investors & Corporate Communications contact:

Almirall

Pablo Divasson del Fraile

pablo.divasson@almirall.com

Tel.: +(34) 93 291 30 87

For more information, please visit almirall.com [linkedin.com/company/almirall](https://www.linkedin.com/company/almirall)

Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.